The global sleep apnea treatment devices market size is set to touch USD 8.97 billion by 2026, exhibiting a CAGR of 8.2% during the forecast period. Steadily climbing demand for sleep apnea devices, stemming from a consistent spread in the prevalence of sleep apnea, will be a major growth driver for this market, shares Fortune Business Insights™ in its new report, titled “Sleep Apnea Treatment Devices Market Size, Share & Industry Analysis, By Device Type (Positive Airway Pressure (PAP) Devices, Oral Appliances, Masks & Accessories, and Others), By End User (Sleep Laboratories & Clinics, and Homecare & Other Settings), and Regional Forecast, 2019-2026.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/sleep-apnea-treatment-devices-market-102694

A study published in the medical journal Lancet in 2019 found that nearly 1 billion people worldwide suffer from Obstructive Sleep Apnea (OSA). Regionally, too, the statistics conform to the global trends. For instance, the European Respiratory Society estimates that 13% to 32% of the geriatric population in Europe suffer from sleep apnea. As a result, the demand for sleep apnea treatment is escalating and driving the sleep apnea treatment devices market trends. Furthermore, the incidence of OSA is spiking owing to the rising prevalence of obesity, the most common cause for interrupted sleep, which according to the World Health Organization, presently affects close to 650 million adults worldwide.

Availability of Advanced Treatment Options to Propel the Market in North America

With a market size of USD 2.35 billion in 2018, North America is poised to dominate the sleep apnea treatment devices market share during the forecast period. The key factors augmenting this regional market include wide availability and high adoption of advanced products, along with growing prevalence of sleep disorders among the populace. In addition to this, supportive health insurance and reimbursement policies are further fueling the uptake of these devices in the region.

In Asia-Pacific, the major driving force for the market is the rising demand for sleep apnea therapies in Japan and the presence of a large, underpenetrated market in the rest of the region. These factors are expected to aid Asia-Pacific to register a considerable CAGR in the upcoming years.

The global cosmetic surgery market is likely to gain traction from the ever-increasing number of patients undergoing procedures, such as chin augmentation, breast reduction, and breast augmentation. The American Society for Aesthetic Plastic Surgery (ASAPS) declared that in 2018, breast reduction (18%) and chin augmentation (20%) were two of the most popular surgical procedures in the U.S.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/cosmetic-surgery-market-102628

This information is given by Fortune Business Insights™ in a recent report, titled, “Cosmetic Surgery Market Size, Share & Industry Analysis, By Type (Surgical Procedures, and Non-Surgical Procedures), By Gender (Males, and Females), By End User (Spas & Cosmetic Surgery Centers, and Hospitals & Specialty Clinics), and Regional Forecast, 2019-2026.” The report further states that the cosmetic surgery market size was USD 50.67 billion in 2018 and is projected to reach USD 66.96 billion by 2026, exhibiting a CAGR of 3.6% during the forecast period.

Expansion of Medical Tourism to Favor Growth in Asia Pacific & Latin America

Geographically, the market is segregated into Latin America, Europe, the Middle East and Africa, North America, and Asia Pacific. Out of these, in 2018, North America generated USD 15.43 billion in terms of cosmetic surgery market revenue. This growth is attributable to the increasing number of surgical procedures performed in the U.S. The International Society of Aesthetic and Plastic Surgeons (ISAPS) stated that in 2018, approximately 4.3 million cosmetic procedures were performed in this country alone. It is combined with the rising per capita expenditure of the populaces in North America. Asia Pacific and Latin America are set to grow considerably in the forthcoming years fueled by the expansion of medical tourism in both these regions.

High Demand for Dermal Fillers Procedure to Accelerate Non-surgical Procedure Segment

In terms of procedure, the market is divided into non-surgical and surgical procedures. Amongst these, in 2018, the surgical procedures segment was in the leading position in the market. Although the number of surgical procedures is much lower than non-surgical procedures across the globe, expensive nature of the former is one of the main factors responsible for high share of the segment. Eyelid surgery, liposuction, and breast augmentation were the top surgical procedures that were performed the most in 2018.

The global drug eluting stents (DES) market size is forecast to reach USD 8.98 billion by 2026, attributable to the increasing prevalence of cardiovascular diseases worldwide. A drug eluting stent is a semi-rigid device in the form of a tube that is coated with a drug that helps to prevent reoccurrence or restenosis of an arterial blockage when released. They help to reduce restenosis cases and also limits the risk of late or early thrombosis in patients.

More information on the market is provided in a recently published report by Fortune Business Insights™ titled, “Drug Eluting Stents (DES) Market Size, Share & Industry Analysis, By Type (Coronary Stenting, and Peripheral Stenting), By Product (Polymer-based, and Polymer-free), By Scaffold (Cobalt-Chromium, Platinum-Chromium, Nitinol and Others), By Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026.” As per this report, the market value was USD 5.71 billion in 2019 and will exhibit a CAGR of 6.7% between 2019 to 2026.

visit: https://www.fortunebusinessinsights.com/drug-eluting-stent-des-market-102612

Improving Healthcare Infrastructure in developing nations will Propel Growth

The increasing cases of cardiovascular diseases worldwide are a significant factor in boosting the global market for drug eluting stents. Besides this, government-supported reimbursement policies and a rise in expenditure on research and development of better stents are also aiding in the expansion of the market. This, coupled with the FDA approvals and CE marks received by many stents, is expected to promote the drug eluting stents market growth in the forecast period.

Rising Incidences of Cardiovascular Diseases will Help Asia Pacific witness Significant Growth

Currently, North America is holding the dominant drug eluting stents market share owing to the increasing prevalence of cardiovascular diseases and the supported reimbursement policies supported by governments in the region. In 2018, this region generated a revenue of USD 1.80 billion. Additionally, the increasing trend of biodegradable polymer-based drug eluting scaffolds may further help this region continue dominance in the forecast period as well. On the other side, the market in Europe will emerge as the fastest-growing region owing to the rise in the number of third-generation DES with the CE mark and the rising popularity of polymer technology for the production of stents. Furthermore, the increasing cases of cardiovascular diseases and the improving medical infrastructure and medical facilities will help Asia Pacific witness significant growth in the coming years.

The rapid adoption of electronic medical records and electronic health records by companies across the world drives the global revenue cycle management market or RCM market. Fortune Business Insights in its new report, titled “Revenue Cycle Management: Global Market Analysis, Insights and Forecast 2018-2025” predicts the market to grow at a remarkable rate during the forecast period. North America is expected to contribute significantly towards the growth of the revenue cycle management market.

Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/revenue-cycle-management-market-100275

Some of the major companies that are present in the Global Revenue Cycle Management Market are;

• Microsoft
• IBM
• Dell
• McKesson
• Experian
• Allscripts
• Athenahealth
• Greenway Health
• GeBBS Healthcare Solutions
• ZirMed, now part of Waystar
• Epic Systems Corporation
• General Electric Manufacturing Company Cerner Corporation

The rising adoption of RCM among end users and presence of well-established healthcare infrastructure is expected to drive the RCM market in North America. In addition to this, revenue cycle management solutions offer long-term benefits, which is a key reason behind its high uptake in the region. Furthermore, the increasing presence of physicians and hospitals in North America will fuel the demand for revenue cycle management services in the coming years.

According to studies, Asia Pacific is projected to exhibit a high growth in the global RCM market. The growth is primarily attributable to the rising target population looking for medical claims and treatment. Moreover, the market is expected to witness exceptional growth opportunities in India, China, Singapore, and Japan.

Advent of IT and Analytics in Healthcare Industry Boosts the Market

Cloud-based solutions are in high demand across the world for seamless data sharing,” stated a lead analyst at Fortune Business Insights. “Several companies are increasingly adopting cloud-based platforms to offer advanced revenue cycle management services,” he added. Robust government initiatives, coupled with decrease in healthcare reimbursements, are likely to drive the RCM market in the coming years. The rising use of analytical tools and IT in the healthcare industry is expected to increase the revenue generated by the RCM market between 2018 and 2025.

The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

Browse More Information on This Report: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668

High Production Scale to Hinder Growth Opportunities in Global Pharmaceutical Space

The COVID-19 contagion is expected to drive the global pharmaceutical industry. Enterprises across the world along with governments from several nations are contributing to the development and distribution of the vaccine. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights™, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.

Highlights of the Report:

While making the report, we segmented the market on the basis of product, type, consumption, distribution channel, and region. Based on the segmentation, we made a list of companies and conducted a detailed analysis of their financial positions, product portfolios, and growth strategies. Our next step included the study of core competencies of key players and their market share to anticipate the degree of competition. The bottom-up procedure was conducted to arrive at the overall size of the market.

Drivers & Restraints-

Mergers and Acquisitions to Help Enterprises Develop Effective Products

The rising adoption of preventive and treatment drugs among children against the disease is expected to drive the growth of the global RSV therapeutics market. In addition, collaborations among key players to develop cost efficient drugs for the treatment of RSV disease is anticipated to increase the demand globally, which is expected to further enhance growth. For instance, in January 2019, Swedish Orphan Biovitrum Ab acquired the distribution rights of Synagis, a respiratory syncytial virus prophylactic drug from AstraZeneca. However, failure of the pipeline drugs in the clinical trials is expected to limit growth.

The global non-Hodgkin lymphoma treatment market size is projected to reach USD 12.57 billion by the end of 2026. The increasing number of regulatory approvals will aid the growth of the market in the coming years. According to a report published by Fortune Business Insights, titled “Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), and Regional Forecast, 2019-2026,” the market was worth USD 6.60 billion in 2018 and will exhibit a CAGR of 8.4% during the forecast period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/non-hodgkin-lymphoma-treatment-market-102642

Some of the leading companies that are operating in the market include:

• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Bayer AG
• Novartis AG
• Kite Pharma, Inc. / Gilead Sciences, Inc.
• Spectrum Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• Janssen Pharmaceuticals, Inc.
• Genentech, Inc. (F. Hoffmann-La Roche Ltd)
• CELGENE CORPORATION (Bristol Myers Squibb Company)
• Merck & Co., Inc.
• Kyowa Kirin Co., Ltd.
• AbbVie Inc.
• Sanofi

Non-Hodgkin lymphoma is a type of cancer that has an effect on the white blood cells of the human body. The disease reduces the immunity of the human body. The severity of the disease has led to a huge emphasis on the R&D of treatment methods. As a result, high investments are being made towards developing efficient treatment methods. The high prevalence of the disease across the world has also caught the eye of investors

Increasing Number of Regulatory Approvals Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of regulatory approvals has made a huge impact on the growth of the overall market. In October 2017, AstraZeneca announced that it has received approval from the US Food and Drug Administration (FDA) for its latest treatment option for non-Hodgkin lymphoma. The company announced that ‘Calquence’ was cleared for use in treatment of patients suffering from the disease

According to a report published by Fortune Business Insights, titled, “Autism Spectrum Disorder Therapeutics Market: Global Market Analysis, Insights and Forecast, 2018-2026,” the global market is likely to reach US$ 4,612.1 Mn by 2026 owing to the rising incidence of autism spectrum disorder worldwide. The report provides valuable insights into the global market trends and factors that are directly affecting the growth of the market.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/autism-spectrum-disorder-therapeutics-market-101207

As per the report, the global autism spectrum disorder therapeutics market was worth US$ 3,293.0 Mn in 2018. Considering the increasing awareness programs regarding this particular disorder and less availability of treatment options, the global market is expected to rise at a moderate CAGR of 4.3% during the forecast period (2019-2026).

The report further states that the number of children diagnosed with autism is increasing day by day across the globe. This, combined with favorable reimbursement scenario, will increase the demand for applied behavioral analysis therapies. Such therapies aid in improving learning and physical disabilities in autistic children. Furthermore, FDA approvals of numerous medicines that are used to manage autism spectrum disorder are expected to propel the global autism spectrum disorder therapeutics market during the forecast period.

Autistic Disorder Segment to Witness Growth Owing to the Rising Prevalence of the Disease

The global autism spectrum disorder therapeutics market is grouped into drug therapy and communication and behavioral therapy in terms of treatment type. Amongst these, the communication and behavioral therapy segment was in the leading position in the global market. Fortune Business Insights predicts that it will retain its position throughout the forecast period. In terms of type, the autism spectrum disorder therapeutics market is classified into Asperger syndrome, autistic disorder, pervasive development disorder, and others. Out of these, the autistic disorder segment procured the highest autism spectrum disorder therapeutics market share in the year 2018

The global E-prescribing market size is projected to reach USD 4,017.79 million by 2026 owing to the implementation of e-prescribing software in the electronic health record solutions that simplified prescription filling over the years. E-prescribing or electronic prescribing is a technology substructure that allows physicians and medical practitioners to send computer-based electronically generated prescriptions to a hospital-based or standalone pharmacy.

For more information in the analysis of this report, visit:  https://www.fortunebusinessinsights.com/e-prescribing-market-102698

It is also cost-efficient and reduces the chances of medication errors by pharmacists. The market is discussed in details in a recently published report by Fortune Business Insights™ titled, “E-prescribing Market Size, Share & Industry Analysis, By Delivery Mode (Web-based, On-premise), By Prescription Type (Controlled substance, Non controlled Substances) By End User (Hospitals, Physician’s offices, Pharmacies) and Regional Forecast, 2019-2026.” As per this report, the market value was USD 863.64 million in 2018 and is expected to rise at a CAGR of 21.0 % in the forecast duration set between 2019 to 2026.

What are the Report Highlights?

The report is based on an in-depth analysis of the market and provides a 360-degree overview of the same. It throws light on significant industry developments, current e-prescribing market trends, and other interesting insights into the market. It discusses factors boosting, repelling, challenging, ad creating opportunities for the market during the forecast period. The report also describes the table of segmentation in detail and mentions the names and figures of the leading segments with their attributed factors. For more information on the report, log on to the company website.

Better Medical Record-Keeping Factor with Electronic-Prescription Solutions to Add Impetus to Market

The increasing adoption of e-prescription based electronic health record (EHR) solutions on a global basis is the key factor boosting the e-prescription market growth. Besides this, electronic prescription system offers better medical history records than handwritten prescriptions. It cannot be forged or exploited, thereby adding to the growth of the market in the forthcoming years. Additionally, rising initiatives taken by both public and private healthcare organizations to integrate e prescribing solutions and eliminate the use of adverse drug events (ADEs) and medical errors will also help to aid in the expansion of the market in the forecast period.

The global pet insurance market size is projected to reach USD 11.25 billion by 2026. The increasing pet adoption in leading countries across the world will have a direct impact on the growth of the market. According to a report published by Fortune Business Insights, titled “Pet Insurance Market Size, Share & Industry Analysis, By Policy Coverage Type (Accident & Illness, Accident Only, Others), By Animal Type (Dog, Cat, Others), By Provider (Public, Private) and Regional Forecast, 2019-2026,” the market was worth USD 6.05 billion in 2018. Driven by flexibility in product offerings, the market will exhibit a CAGR of 8.0% during the forecast period, 2019-2026.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/pet-insurance-market-101956

A few of the leading companies that are operating in the global market include:

• Trupanion
• Anicom Holdings
• Nationwide Mutual Insurance Company
• ASPCA
• Healthy Paws Pet Insurance, LLC.
• Embrace Pet Insurance Agency, LLC
• Figo Pet Insurance LLC.
• Agria Pet Insurance Ltd
• 24PetWatch

The pet insurance market will benefit from the increasing pet adoption in leading countries across the world. Pet insurance refers to a policy that covers medical as well as accidental factors that is associated with the pets. The emphasis on the well-being and health of pets, by private as well as government organizations will create several growth opportunities. The presence of several private organizations offering premium insurance policies will have a positive impact on the growth of the market in the forthcoming years. Several companies are focused on offering novel services as well as concessions in a bid to establishing a stronghold in the market. These factors will aid the growth of the market in the coming years.

Europe to Emerge Dominant; Influx of Start-ups to Aid Growth

The report analyzes the ongoing pet insurance market trends across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among these regions, the market in Europe generated the highest market revenue in 2018. Europe is projected to dominate the market in the coming years driven by the increasing number of start-ups in several countries across this region. The increasing number of government initiatives to promote animal wellness and health, coupled with encouragement for pet adoption, will aid the growth of the market in this region. Besides Europe, the market in North America will exhibit considerable CAGR. As of 2018, the market in North America was worth USD 1.42 billion and this value is likely to increase further in the coming years.

The Assisted Reproductive Technologies (ART) market size is projected to reach USD 45.06 billion by 2026, exhibiting a CAGR of 9.8% during the forecast period. The market was valued at USD 21.32 billion in 2018. This information is published in a recent report by Fortune Business Insights, titled, “Assisted Reproductive Technologies (ART) Market Size, Share & Industry Analysis, By Technique (In-Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), and Others), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End User (Fertility Clinics, and Hospitals) and Regional Forecast, 2019-2026.” As per the report, increasing stress levels amongst the population is likely to result in the rising prevalence of infertility. It will aid in the fertility services market growth during the forecast period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/assisted-reproductive-technology-art-market-101811

Rising Awareness Campaigns Regarding Cost-effective Procedures Will Boost Growth

In countries, such as India, the U.K, U.S., and China, there is a high prevalence of infertility. It will increase the demand for advanced ART technologies and procedures. The National Survey of Family Growth (NSFG) stated that around 6.7% of women residing in the U.S. were affected by infertility in 2018. The age group was between 15 to 44 years. Moreover, it is not only the women who are suffering from infertility nowadays.

The Oxford Journals published a study that mentioned that in the U.K., one out of ten men from the age group of 16 to 74 years is affected by infertility. The rate is rising worldwide owing to the increasing cases of obesity, rising stress level and a rapid inclination towards a sedentary lifestyle. Besides, numerous government and non-profit agencies in the developed, as well as developing nations, are implementing awareness campaigns to educate the general populaces regarding the cost-effective fertility treatments. These are some of the crucial assisted reproductive technologies market trends that are set to augment ART market growth.

Europe to Dominate: Increasing Prevalence of Fertility to Favor Growth

The assisted reproductive technologies market is geographically segregated into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Out of these, Europe had acquired USD 8.78 billion ART market revenue in 2018. It is expected to retain its dominance throughout the forthcoming years. This growth is attributable to the rising incidence of infertility that is further leading to increasing demand for ART procedures.